Resources and Support for You and Your Patients

Find a treatment site

LUTATHERA treatment sites in the United States are shown below (map current as of March 31, 2020).

Advocate Lutheran General Hospital

Arizona Center for Hematology and Oncology

Baptist Memorial Hospital Memphis

Baton Rouge General Medical Center

Cancer Specialist of North Florida

Cancer Treatment Center of America

CHI Health- Lakeside Hospital

CHI Health- West Omaha Imaging

City of Hope Medical Center

Cleveland Clinic Main Campus

Dana Farber Cancer Institute

Dartmouth Hitchcock Medical Center

DLP Conemaugh Memorial Medical Center LLC

Duke University Health System

Emory University Hospital Midtown

FL Cancer Spec - Good Samaritan Flagler

Florida Cancer Specialist - Gladiolus

Florida Cancer Specialists Ocala Center

Florida Cancer Specialists, Brookville

Greenville Memorial Hospital

H Lee Moffitt Cancer Center and Research Institute

Hackensack Meridian Health

Hines VA Medical Center

Hoag Hospital -Newport Beach-Advanced Technology

Jackson Madison County General Hospital

Joe Arrington Cancer Center

Kaiser Foundation Hospital

Kaiser Permanente - Antioch Medical CTR

Kaiser Permanente - Los Angeles Medical Center

Kaiser Permanente - Medical Ctr. Sacramento

Kaiser Permanente - Panorama City

Kaiser Permanente - San Bernardino County

Kaiser Permanente - Santa Clara Medical Center

Kaiser Permanente - South Baltimore

Kaiser Permanente - Woodland Hills Medical Center

Kaiser Permanente Zion Medical Center

Karmanos Cancer Institute

Loma Linda University Medical Center

Louis Stokes VA Medical Center

Loyola University Health System

Massachusetts General Hospital

Medical University Hospital Authority

Medstar Georgetown University Hospital

Medstar Washington Hospital Center

Memorial Hermann Hospital

Memorial Sloan Kettering Cancer Center

Mercy Medical Center, Glen Burnie

Methodist Dallas Medical Center

Michigan Health Professionals

Midwestern Regional Medical Center

Missouri Baptist Medical Center

Nebraska Cancer Specialist

New York-Presbyterian - Columbia Hospital

New York-Presbyterian - Weil Cornell Medical Center

Northwestern Memorial Hospital

Novant Health Presbyterian Medical Center

NYU Langone Medical Center

Ochsner LSU Health Shreveport

Penn State Hershey Medical Center

Providence Regional Medical Center

Regional Cancer Care Associates Monroe

Robert Wood Johnson University Hospital

Roswell Park Cancer Institute

Rush University Medical Center

Saint Francis Cancer Center

Saint Francis Hospital - Tulsa

Seattle Cancer Care Alliance SCCA

Sentara Norfolk General Hospital

Southeast Nebraska Hematology & Oncology Consultants

Southeastern Regional Medical Center- Cancer Treatment Centers of America

Spartanburg Regional Health Service

SSM Health Saint Louis University Hospital

SSM Health St. Anthony Hospital

SSM Health St. Mary's Hospital - Madison

St. Joseph's Hospital and Medical Center

St. Luke's Medical Center (Aurora HC)

St. Luke's University Hospital (Bethlehem)

The University of Texas Health Science Center

Tristar Centennial Medical Center

UF Health Gainesville Nuclear Science Bldg

University Hospitals of Cleveland Medical Center

University of Arkansas for Medical Science (UAMS)

University of California Davis

University of California Los Angeles Medical Center

University of Chicago Medical Center

University of Colorado Hospital

University of Connecticut Health Center

University of Kansas Cancer Center - Westwood

University of Miami Hospital & Clinics

University of Pennsylvania Health System

University of Pittsburgh Medical Center

University of Texas MD Anderson Cancer Center

University of Texas Southwestern Medical Center

University of Wisconsin Hospital

VA Greater Los Angeles Healthcare System

VA North Texas Health Care System

VA Palo Alto Health Care System

Vanderbilt University Medical Center

Virginia Cancer Specialists

Virginia Mason Medical Center

Wake Forest Baptist Medical Center

Walter Reed National Military Medical Center

Washington University - St Louis

West Virginia University Hospital

Willis-Knighton Cancer Center

Yale New Haven Hospital

Load More

Go to for access information and assistance from AAA PatientCONNECT

AAA PatientCONNECTTM provides services to facilitate your patients’ access to LUTATHERA® treatment. This may include:

Patient Financial Assistance*

  • Uninsured patient assistance
  • Commercial patient copay assistance

Other Assistance

  • Insurance benefits verification
  • Prior authorization eligibility check

For more information, and to download reimbursement resources, visit

*Eligibility restrictions may apply. For full terms and conditions, please call AAA PatientCONNECTTM at 1-844-NETS-AAA. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the copayment support provided under this program, eg, copay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payers of benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law or restricted.

It is the provider’s responsibility to determine and submit accurate information on claims and comply with payer coverage, reimbursement, and claim submission rules. Information in this presentation does not represent any statement, promise, or guarantee by AAA about coverage, levels of reimbursement, payment, or charge.



  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer. Radiation can be detected in the urine for up to 30 days following LUTATHERA administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with LUTATHERA consistent with institutional good radiation safety practices and patient management procedures.
  • Myelosuppression: In NETTER-1 clinical trial, myelosuppression occurred more frequently in patients receiving LUTATHERA with long acting octreotide at the following rates (all grades/grade 3 or 4): anemia (81%/0), thrombocytopenia (53%/1%), and neutropenia (26%/3%). Blood cell counts must be monitored prior to, during, and after treatment. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.
  • Secondary Myelodysplastic Syndrome and Leukemia: In NETTER-1, with a median follow-up time of 24 months, myelodysplastic syndrome (MDS) was reported in 2.7% of patients receiving LUTATHERA with long-acting octreotide. In ERASMUS, a Phase I/II clinical study, 15 patients (1.8%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to the development of MDS was 28 months (9 to 41 months) and 55 months (32 to 155 months) for acute leukemia.
  • Renal Toxicity: Treatment with LUTATHERA will expose kidneys to radiation, which may impair renal function. In ERASMUS <1% of patients developed renal failure 3 to 36 months following LUTATHERA. Monitor serum creatinine and creatinine clearance to assess changes in renal function. Advise patients to urinate frequently during and after administration of LUTATHERA. A concomitant intravenous infusion of amino acids before, during and after LUTATHERA administration is mandatory for renal protection. Patients with baseline renal impairment may be at greater risk of toxicity. Perform more frequent assessments of renal function in patients with mild or moderate impairment. Withhold, reduce dose, or permanently discontinue based on severity of reaction. Do not decrease the dose of amino acid solution if the dose of LUTATHERA is reduced. LUTATHERA has not been studied in patients with severe renal impairment (CrCL < 30 mL/min).
  • Hepatotoxicity: In ERASMUS, <1% of patients were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, and serum albumin during treatment. Withhold, reduce dose, or permanently discontinue based on severity of reaction.
  • Neuroendocrine hormonal crisis: Manifesting with flushing, diarrhea, bronchospasm and hypotension, neuroendocrine hormonal crisis occurred in 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial LUTATHERA dose. Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated.
  • Embryo-Fetal Toxicity: LUTATHERA can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the final dose. Verify pregnancy status of females of reproductive potential prior to initiating LUTATHERA.
  • Risk of Infertility: LUTATHERA may cause infertility in males and females. Radiation absorbed by testis and ovaries from the recommended cumulative LUTATHERA dose falls within the range in which temporary or permanent infertility can be expected following external beam radiotherapy.


The most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence in LUTATHERA arm) observed in NETTER-1 were lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea (5%), elevated AST (5%), increased ALT (4%), hyperglycemia (4%), and hypokalemia (4%).

In ERASMUS, the following serious adverse reactions have been observed with a median follow-up time of more than 4 years after treatment with LUTATHERA: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%). Patients should be counseled and monitored in accordance with the LUTATHERA Prescribing Information.


Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended.


  • Lactation: Because of the potential risk for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with LUTATHERA and for 2.5 months after the final dose.

To report the side effects electronically please click below:

If you want to learn more about our products, please complete this request. Note this request is only used to ask general information.

Please see full Prescribing Information.

Distributed by: Advanced Accelerator Applications USA, Inc., NJ 07041

References: 1. LUTATHERA® [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; July 2018.

This site is intended for Healthcare Professionals in the United States. By clicking "Continue" you confirm you are a Healthcare Professional.

Healthcare professionals
continue to site


Patients/family members
visit patient site

Patient site